Stock ENZ ENZO BIOCHEM, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Enzo Biochem, Inc.

Equities

ENZ

US2941001024

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.05 USD -1.87% Intraday chart for Enzo Biochem, Inc. -3.67% -24.46%
Mar. 15 North American Morning Briefing : Inflation Worries Continue to Weigh on Mood DJ
Mar. 13 Enzo Biochem, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 CI

Valuation

Fiscal Period: July 2018 2019 2020 2021 2022 2023
Capitalization 1 208.5 185.9 114 158 115.5 73.6
Enterprise Value (EV) 1 149 130.8 98.91 137.2 114.5 -1.777
P/E ratio -20.1 x 78.2 x -3.97 x 20.4 x -6.24 x 3.59 x
Yield - - - - - -
Capitalization / Revenue 1.99 x 2.29 x 1.5 x 1.34 x 1.08 x 2.37 x
EV / Revenue 1.42 x 1.61 x 1.3 x 1.17 x 1.07 x -0.06 x
EV / EBITDA -16.5 x -5.41 x -3.59 x 41 x -9.32 x 0.08 x
EV / FCF -191 x -5.69 x -9.44 x -28.6 x -7.61 x -0.11 x
FCF Yield -0.52% -17.6% -10.6% -3.5% -13.1% -932%
Price to Book 2.57 x 2.16 x 1.95 x 2.3 x 2.12 x 0.94 x
Nbr of stocks (in thousands) 47,166 47,557 47,891 48,472 48,720 49,728
Reference price 2 4.420 3.910 2.380 3.260 2.370 1.480
Announcement Date 10/15/18 10/15/19 10/19/20 10/12/21 10/14/22 11/3/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: July 2018 2019 2020 2021 2022 2023
Net sales 1 104.7 81.17 76.02 117.7 107.1 31.06
EBITDA 1 -9.034 -24.16 -27.59 3.345 -12.28 -22.05
EBIT 1 -12.16 -27.19 -30.37 0.692 -15.11 -24.74
Operating Margin -11.62% -33.5% -39.95% 0.59% -14.11% -79.64%
Earnings before Tax (EBT) 1 -11.42 2.489 -28.52 7.875 -18.26 -25.02
Net income 1 -10.32 2.489 -28.52 7.875 -18.26 20.29
Net margin -9.86% 3.07% -37.52% 6.69% -17.06% 65.32%
EPS 2 -0.2200 0.0500 -0.6000 0.1600 -0.3800 0.4117
Free Cash Flow 1 -0.7805 -23.01 -10.48 -4.804 -15.03 16.57
FCF margin -0.75% -28.34% -13.78% -4.08% -14.04% 53.35%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - 81.68%
Dividend per Share - - - - - -
Announcement Date 10/15/18 10/15/19 10/19/20 10/12/21 10/14/22 11/3/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: July 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 59.5 55.2 15.1 20.8 1.02 75.4
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -0.78 -23 -10.5 -4.8 -15 16.6
ROE (net income / shareholders' equity) -12.1% 2.98% -39.5% 12.4% -29.7% -37.6%
ROA (Net income/ Total Assets) -7.26% -16.3% -17.3% 0.38% -9.01% -15.7%
Assets 1 142.1 -15.25 164.7 2,060 202.6 -129.6
Book Value Per Share 2 1.720 1.810 1.220 1.410 1.120 1.570
Cash Flow per Share 2 1.270 1.260 1.000 0.2800 0.4400 1.650
Capex 1 1.89 8.13 2.17 4.44 3.47 2.76
Capex / Sales 1.8% 10.01% 2.85% 3.77% 3.24% 8.89%
Announcement Date 10/15/18 10/15/19 10/19/20 10/12/21 10/14/22 11/3/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ENZO BIOCHEM, INC. Stock Enzo Biochem, Inc.
-24.46% 53.79M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ENZ Stock
  4. Financials Enzo Biochem, Inc.